Session speakers at SupplySide Global 2026 covered consumer survey data, extraction methods, dosing, and claims for formulators working with functional mushrooms in beverages and foods.
The policy is a drug-compounding framework, not a supplement pathway, but it changes the regulatory backdrop for peptide products, drug preclusion arguments, and gray-market competition.
Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.